<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364914">
  <stage>Registered</stage>
  <submitdate>6/09/2013</submitdate>
  <approvaldate>10/09/2013</approvaldate>
  <actrnumber>ACTRN12613001001785</actrnumber>
  <trial_identification>
    <studytitle>The effect of soy isoflavones and kiwifruit on bone turnover, hormone levels, blood lipids and faecal microflora in menopausal women. 

</studytitle>
    <scientifictitle>The effect of soy isoflavones in combination with green kiwifruit on bone turnover, hormone levels, blood lipids and faecal microflora in menopausal women. 

</scientifictitle>
    <utrn>U1111-1147-6503 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <healthcondition>Blood lipids</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a cross over study. There are two interventions. One with 40mg Soy isoflavones in two tablets/day only and the other with 40mg soy isoflavones plus 2 kiwifruit per day. The intervention is for 2 periods of 6 weeks. There is one washout period of 2 weeks before the start of the trial; one arm starting on the soy isoflavones tablets only and the other arm with kiwifruit in combination with the soy isoflavones.  After 6 weeks there is a second washout period of 2 weeks before the two arms cross over. The supplementation is for another 6 weeks. Adherence will be recorded in a diary. </interventions>
    <comparator>The isoflavones only group is the comparator.</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bone markers urinary deoxypyridinoline, plasma C-telopeptide of Type I collagen, and serum undercarboxylated osteocalcin. </outcome>
      <timepoint>baseline and six weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Blood and urine daidzein, genistein and equol</outcome>
      <timepoint>Baseline and week 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood lipids</outcome>
      <timepoint>Baseline and week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood estradiol</outcome>
      <timepoint>Baseline and week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Faecal microflora</outcome>
      <timepoint>Baseline and week 6 after kiwifruit consumption only. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy post-menopausal women aged between 50-65 will be recruited.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria are as follows: osteoporosis at the hip or spine; history of chronic renal or hepatic disease, history of hormone therapy use or breast cancer, soy allergies, and use of any other medication known to affect the skeleton or antibiotics that will affect gut microflora. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed. </concealment>
    <sequence>Excel spread sheet</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Power calculation for bone marker analysis:

Serum CTx (cross linked C- telopeptide of type 1 collagen): 20 subjects per group
The sample size calculation showed that with 20 subjects in each group, a difference of 0.09 ng/ml between the means of serum CTx concentration could be shown with a power of 0.80 and a two-side type 1 error of 0.05.

Serum ucOC (under carboxylated osteocalcin): 25 subjects per group
The sample size calculation showed that with 25 subjects in each group, a difference of 1.35 ng/ml between the means of serum ucOC concentration could be shown with a power of 0.80 and a two-side type 1 error of 0.05.

Urinary DPD (Deoxypyridinoline): 27 subjects per group
The sample size calculation showed that with 27 subjects in each group, a difference of 1.79 nM/mM Cr between the means of urinary DPD concentration could be shown with a power of 0.80 and a two-side type 1 error of 0.05.

Analysis will be with repeated measures ANOVA; 2 way ANOVA. Results of the bone markers, lipids and hormones will be expressed as % change from baseline. 
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>6/09/2013</anticipatedstartdate>
    <actualstartdate>2/09/2013</actualstartdate>
    <anticipatedenddate>10/09/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zespri International</primarysponsorname>
    <primarysponsoraddress>400 Maunganui Road, Mount Maunganui, 3116, New Zealand.</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Business, Innovation and Employment</fundingname>
      <fundingaddress>33 Bowen Street, Wellington 6011, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Y Ishimi</othercollaboratorname>
      <othercollaboratoraddress>National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, 162-8636, Tokyo, Japan. </othercollaboratoraddress>
      <othercollaboratorcountry>Japan</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Y Tousen</othercollaboratorname>
      <othercollaboratoraddress>National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, 162-8636, Tokyo, Japan. </othercollaboratoraddress>
      <othercollaboratorcountry>Japan</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the effects of soybean isoflavones in combination with kiwifruit on equol production and bone health in menopausal women. We hypothesize that the kiwifruit will affect gut microflora and the metabolism of the soy isoflavones. </summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>None</publicnotes>
    <ethicscommitee>
      <ethicname>Southern A</ethicname>
      <ethicaddress>Massey University, Private Bag 11222, Palmerston North 4442</ethicaddress>
      <ethicapprovaldate>7/08/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>25/06/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Marlena Kruger</name>
      <address>Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11222, Palmerston North 4442</address>
      <phone>+6463505905</phone>
      <fax>+6463505446</fax>
      <email>m.c.kruger@massey.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Marlena Kruger</name>
      <address>Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11222, Palmerston North 4442</address>
      <phone>+6463505905</phone>
      <fax />
      <email>m.c.kruger@massey.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Marlena Kruger</name>
      <address>Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11222, Palmerston North, 4442</address>
      <phone>+6463505905</phone>
      <fax />
      <email>m.c.kruger@massey.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>